EP0398879A1 - Amino acid composition for parenteral nutritional support and the use thereof - Google Patents

Amino acid composition for parenteral nutritional support and the use thereof

Info

Publication number
EP0398879A1
EP0398879A1 EP88909629A EP88909629A EP0398879A1 EP 0398879 A1 EP0398879 A1 EP 0398879A1 EP 88909629 A EP88909629 A EP 88909629A EP 88909629 A EP88909629 A EP 88909629A EP 0398879 A1 EP0398879 A1 EP 0398879A1
Authority
EP
European Patent Office
Prior art keywords
composition
glutamine
optionally
alpha
ketoglutarate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP88909629A
Other languages
German (de)
English (en)
French (fr)
Inventor
Erik Vinnars
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vinnars Erik AB
Original Assignee
Vinnars Erik AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vinnars Erik AB filed Critical Vinnars Erik AB
Publication of EP0398879A1 publication Critical patent/EP0398879A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • Amino acid composition for parenteral nutritional support and the use thereof.
  • the present invention relates to a composition for therapeutic, especially postoperative and post ⁇ traumatic, parenteral nutritional support treatment, which composition, in addition to conventional amino acid components, also contains L-glutamine and/or its derivative alpha-ketoglutarate, and optionally L-asparagine and acetoacetate.
  • parenteral nutritional sup ⁇ port In severe states of illness and injuries, and in postoperative states, parenteral nutritional sup ⁇ port is generally applied.
  • preparations for intraveneous nutritional support generally con ⁇ tained an aqueous solution of a high caloric content carbohydrate, such as glucose and the like, and elec ⁇ trolytes.
  • the nitrogen balance of the body In prolonged states of illness or in injuries and surgical operations, the nitrogen balance of the body must however be considered, i.e. the ratio of nitrogen loss to nitrogen intake.
  • the parenteral nutritional support can be supplemented with amino acid supply to improve the nitrogen balance. Different amino acid compositions for parenteral supply are previously known, see e.g.
  • said vital amide derivatives can be brought into a form suitable for administration by sterile filtration of an aqueous solution, followed by rapid cooling and cold storage limited to a few months.
  • One alternative is freeze-dry- ing the sterile-filtered solution, yielding a sterile powder. Immediately before administration, this powder can be added to a conventional amino acid mixture. Also other forms of powder sterilisation, not relying on heat, are conceivable. The possibility of using the Na salt of the compounds in order to increase the solubility has also been considered.
  • the invention thus relates to a composition for therapeutic, especially postoperative and posttraumatic, parenteral nutritional support treatment, which composi ⁇ tion is based on a conventional amino acid mixture, the composition comprising L-glutamine and/or alpha- ketoglutarate, and optionally L-asparagine and/or acetoacetate, the components of the composition, ex- pressed in g dry component/1 aqueous solution, being:
  • composition being characterised in that it also contains 5-30 g/1 L-glutamine and/or 5-25 g/1 alpha- ketoglutarate, and optionally 0.5-10 g/1 L-asparagine and optionally 0.5-10 g/1 acetoacetate, or salts or esters thereof.
  • a preferred amount of L-glutamine in the composi ⁇ tion of the present invention is 10-30 g/1 and an especially preferred amount is 15-25 g/1, specifically 20 g/1.
  • a preferred amount of alpha-ketoglutarate in the composition of the present invention is 10-25 g/1, specifically 16.5 g/1.
  • compositions have included the following suitable components (ex ⁇ pressed in g dry component/1 aqueous solution) :
  • Example 1 2 3 4 5 glycine 5.9 5.9 5.9 5.9 5.9 aspartate 4.8 4.8 4.8 4.8 4.8 gluta ate 6.8 6.8 6.8 6.8 6.8 alanine 12 12 12 12 12 12 12 arginine 8.4 8.4 8.4 8.4 8.4 cysteine/cystine 0.42 0.42 0.42 0.42 histidine 5.1 5.1 5.1 5.1 isoleucine 4.2 4.2 4.2 4.2 4.2 4.2 4.2 leucine 5.9 5.9 5.9 5.9 l sine 6.8 6.8 6.8 6.8 6.8 6.8 methionine 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 phenylalanine 5.9 5.9 5.9 5.9 5.9 5.9 5.9 5.9 proline 8.0 8.0 8.0 8.0 serine 6.0 6.0 6.0 6.0 6.0 threonine 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 4.2 tryptophan 1.4 1.4 1.4 1.4 1.4 tyrosine 0.4 0.4
  • alpha-ketoglutarate - 16.5 10 10 10 asparagine 2 4 acetoacetate - - - 2
  • alpha-ketoglutarate should be included in the composition, it must be added in the form of its sodium salt or its esters, since it is otherwise ex ⁇ tremely sparingly soluble.
  • the glutamine can also be added in the form of the sodium salt thereof, thus improving its solubility.
  • the invention also relates to the use of L-glutamine and/or its derivative alpha-ketoglutarate and optionally L-asparagine and/or acetoacetate for the preparation of a composition intended for therapeutic, especially postoperative and posttraumatic, parenteral nutritional support treatment, which use is characterised in that L-glutamine and/or alpha-ketoglutarate and optionally L-asparagine and/or acetoacetate or salts or esters thereof, dissolved in water and sterile-filtered, are added in cold-stored and freeze-dried form or other sterile powder form to a commercial amino acid nutrient solution immediately before the therapeutic treatment.
  • L-glutamine, alpha-ketoglutarate and optionally L-asparagine and/or acetoacetate or salts or esters thereof are dissolved in sterile pyrogen-free water at 30-50°C.
  • the solution is sterile-filtered and rapidly cooled and may thereafter be stored for a few months in a solution in a cooled state or for an even longer time in the frozen state, or stored after freeze-drying for several years in sterile powder form, until it should be used together with an amino acid solution of conventional commercial type, for instance of the Vamin ® type (amino acid nutrient compo ⁇ sition from KabiVitrum AB) .
  • Carbohydrates and fatty substances can also be added to the infusion solution.
  • alpha-ketogutarate When using alpha-ketogutarate, this must be added in the form of its sodium salt or its esters, which is also possible, but not necessary, in the case of L-glutamine.
  • a newly prepared composition as above, either in large bags or in separate vials for each substrate, is then administered to patients exhibiting disordered nitrogen balance, resulting either from a surgical ope- ration or from an injury or illness, the administration being conducted during a period of from 2-4 days to several weeks or until the patient can start eating ordinary food, with a dosage of 120-170 kJ/kg body weight/day, including 0.1-0.2 g amino acid nitrogen/kg body weight/day.
  • Urine was collected continuously and analysed for urea content. On the basis hereof, it is possible to calculate the nitrogen balance, see MacKenzie et al, A simple method for estimating nitrogen balance in hospitalized patients: A review and supporting data for a previously proposed technique. J. Am.Col. Nutr. _4:575-581 (1985). In the control group, the nitrogen balance was clearly negative each day during the mea ⁇ suring period of 3 days while, in the test group, it was statistically less negative, however with a substantial spread of the values for day 2. These values are given in the following Table as means deviation.
  • the protein synthesis in skeletal muscle was estimated by determining the total ribosome concen ⁇ tration and the percentage proportion of polyribo- somes, see Wernerman et al: Size distribution of ribo- somes in biopsy specimens of human skeletal muscle during starvation. Metabolism 34, 7:665-669, 1985. In the control group, an appreciable reduction of these values was obtained while, in the test group, they remained substantially unchanged after the sur ⁇ gery, see the following Table where the values relate 'to day 3.
  • the intracellular concentration of glutamine in skeletal muscle was affected by the TPN program containing glutamine.
  • the glutamine concentration in mmole/1 intracel ⁇ lular water in skeletal muscle prior to surgery and on the third postoperative day was as follows:
  • the above Tables show that the nitrogen balance and, thus, the postoperative recovery are favourably affected upon parenteral administration of the claimed composition as compared with the control group receiving a conventional composition.
  • the Tables further show that the postoperative obligate reduction of the total ribosome concentration and the percentage proportion of polyribosomes could be prevented in the test group, and that the glutamine reduction in skeletal muscle was lower in the glutamine group.
  • test group was also given 0.136 g alpha-ketoglutarate ( ⁇ -KG)/kg body weight/day. Thus, both groups were given isonitrogenous and isocaloric amounts of amino acid and energy. Electrolytes, tracer metals and vita ⁇ mins were administered to both groups.
  • the daily nitrogen balance in means + SEM was as follows: ⁇ -KG -0.54+0.53 -1.65+1.86 -0.15+1.07 -2.33+1.30
  • the glutamine concentration (in mmole/kg wet weight) in skeletal muscle was affected in the following manner.
  • the present amino acid nutrient compositions thus have a very favourable effect on postoperative and posttraumatic states since they provide an im ⁇ proved nitrogen balance and unaltered protein syn ⁇ thesis capacity and, hence, promote a considerably quicker and improved recovery of patients than is the case of previously known amino acid nutrient com- positions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP88909629A 1987-10-29 1988-10-28 Amino acid composition for parenteral nutritional support and the use thereof Pending EP0398879A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8704217 1987-10-29
SE8704217A SE8704217D0 (sv) 1987-10-29 1987-10-29 Aminosyrakomposition for parenteral neringstillforsel

Publications (1)

Publication Number Publication Date
EP0398879A1 true EP0398879A1 (en) 1990-11-28

Family

ID=20370052

Family Applications (2)

Application Number Title Priority Date Filing Date
EP88909629A Pending EP0398879A1 (en) 1987-10-29 1988-10-28 Amino acid composition for parenteral nutritional support and the use thereof
EP88850373A Expired - Lifetime EP0318446B1 (en) 1987-10-29 1988-10-28 Amino acid composition for parenteral nutritional support

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP88850373A Expired - Lifetime EP0318446B1 (en) 1987-10-29 1988-10-28 Amino acid composition for parenteral nutritional support

Country Status (10)

Country Link
EP (2) EP0398879A1 (enrdf_load_html_response)
JP (1) JP2728134B2 (enrdf_load_html_response)
AT (1) ATE81468T1 (enrdf_load_html_response)
AU (1) AU2623888A (enrdf_load_html_response)
CA (1) CA1314232C (enrdf_load_html_response)
DE (1) DE3875322T2 (enrdf_load_html_response)
ES (1) ES2046331T3 (enrdf_load_html_response)
GR (1) GR3006085T3 (enrdf_load_html_response)
SE (1) SE8704217D0 (enrdf_load_html_response)
WO (1) WO1989003688A1 (enrdf_load_html_response)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649746B1 (en) 1999-05-07 2003-11-18 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8902544L (sv) * 1989-07-17 1991-01-18 Kabivitrum Ab Beredning foer naeringstillfoersel, samt saett foer dess framsaellning
CA2068333A1 (en) * 1990-09-10 1992-03-11 Austin L. Shug Composition and method for protecting the heart during reperfusion
SE9003844L (sv) * 1990-12-03 1992-06-04 Kabi Pharmacia Ab Naeringstillsats
US5334380A (en) * 1991-09-27 1994-08-02 Board Of Regents, The University Of Texas System Anti-endotoxin, interleukin-1 receptor antagonist and anti-tumor necrosis factor antibody with arginine-free formulations for the treatment of hypotension
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
WO1993005780A1 (en) * 1991-09-27 1993-04-01 Board Of Regents, The University Of Texas System Amino acids containing parenteral formulations for the treatment of hypotension and related pathologies
US5374651A (en) * 1991-09-27 1994-12-20 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of hypotension with arginine free essential and essential amino acids and arginine derivatives
GB9121467D0 (en) * 1991-10-10 1991-11-27 Sandoz Nutrition Ltd Improvements in or relating to organic compounds
SE9201584D0 (sv) * 1992-05-20 1992-05-20 Vinnars Erik Ab Use of alpha-ketoglutarate
US5646187A (en) * 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
US5276018A (en) * 1992-07-17 1994-01-04 Brigham And Women's Hospital Composition comprising amino acids and methods for decreasing muscle breakdown
FR2711529B1 (fr) * 1993-10-28 1996-07-05 Clintec Nutrition Cy Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme.
SE9303691D0 (sv) * 1993-11-09 1993-11-09 Gramineer Ab New beverage
SE9402027D0 (sv) * 1994-06-10 1994-06-10 Pharmacia Ab Energy substrates
US6100287A (en) * 1997-11-13 2000-08-08 University Of Florida Materials and methods for enhancing muscle performance and recovery from fatigue
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
US20020147237A1 (en) * 2001-01-31 2002-10-10 Lars Wiklund Preservation of bodily protein
EP1618878A1 (en) * 2003-04-30 2006-01-25 Ajinomoto Co., Inc. Body-temperature lowering depressant
JP4528925B2 (ja) * 2003-05-30 2010-08-25 独立行政法人理化学研究所 アミノ酸組成物及び補液
WO2005027898A1 (ja) * 2003-09-19 2005-03-31 Riken アミノ酸組成物
JP4124260B2 (ja) 2004-09-17 2008-07-23 味の素株式会社 機能性消化管障害予防・改善剤及び食品
JP5177785B2 (ja) * 2004-11-02 2013-04-10 味の素株式会社 周術期患者用薬剤
PL379512A1 (pl) * 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3026368A1 (de) * 1980-07-11 1982-02-18 Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München Naehrloesung fuer die vollstaendige parenterale ernaehrung und fuer gesteigerte energieproduktion
JPS5916817A (ja) * 1982-07-16 1984-01-28 Eisai Co Ltd アミノ酸輸液
JPS5927817A (ja) * 1982-08-05 1984-02-14 Tanabe Seiyaku Co Ltd アミノ酸輸液
FR2556593B1 (fr) * 1983-12-20 1987-01-02 Synthelabo Composition nutritive contenant de l'acide alpha-cetoisocaproique, de la leucine et des acides amines essentiels et non essentiels
JPS6178719A (ja) * 1984-09-25 1986-04-22 Tanabe Seiyaku Co Ltd 総合輸液剤
CA1285491C (en) * 1985-09-12 1991-07-02 Robert J. Smith Method of treating catabolic dysfunction
WO1987003806A1 (en) * 1985-12-18 1987-07-02 Veech Richard L Parenteral nutrition therapy with amino acids
JPS62221621A (ja) * 1986-03-24 1987-09-29 Tanabe Seiyaku Co Ltd 総合輸液剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8903688A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649746B1 (en) 1999-05-07 2003-11-18 University Of Virginia Patent Foundation Biological production of stable glutamine, poly-glutamine derivatives in transgenic organisms and their use for therapeutic purposes

Also Published As

Publication number Publication date
ATE81468T1 (de) 1992-10-15
WO1989003688A1 (en) 1989-05-05
GR3006085T3 (enrdf_load_html_response) 1993-06-21
DE3875322D1 (de) 1992-11-19
EP0318446B1 (en) 1992-10-14
SE8704217D0 (sv) 1987-10-29
JPH03500775A (ja) 1991-02-21
DE3875322T2 (de) 1993-05-13
CA1314232C (en) 1993-03-09
JP2728134B2 (ja) 1998-03-18
EP0318446A1 (en) 1989-05-31
AU2623888A (en) 1989-05-23
ES2046331T3 (es) 1994-02-01

Similar Documents

Publication Publication Date Title
WO1989003688A1 (en) Amino acid composition for parenteral nutritional support and the use thereof
US3950529A (en) Amino acid formulations for patients with liver disease and method of using same
EP0705542B1 (en) Adolescent dietary composition
US5719119A (en) Parenteral nutrition therapy with amino acids
HK1005768B (en) Adolescent dietary composition
JP4011638B2 (ja) 経口経腸栄養組成物
US5646187A (en) Use of alpha-ketoglutarate
US5310768A (en) Method for improving the glutamine content in skeletal muscle and composition therefore
JP3137273B2 (ja) 糖尿病に有効な組成物
WO1993023027A1 (en) Use of alpha-ketoglutarate
JPS61502822A (ja) 全非経口栄養及び経腸栄養組成物
JP2683129B2 (ja) 栄養組成物
JPS61186320A (ja) アミノ酸製剤
Meguid et al. Effect of elemental diet on albumin and urea synthesis: comparison with partially hydrolyzed protein diet
JP3914585B2 (ja) マクロファージ一酸化窒素産生亢進剤
EP0355453A2 (en) Use of 3-hydroxybutyric acid as an energy source
WO1982003552A1 (en) Improved solution for parenteral nutrition
JPS5923291B2 (ja) アミノ酸および無機塩を含有する注入液
Maksoud et al. Effect of branched‐chain amino acids and insulin on postinjury protein catabolism in growing animals
JPH07267855A (ja) グルタミン産生剤
Deutz et al. Intragastric bolus feeding of meals containing elementary, partially hydrolyzed or intact protein causes comparable changes in interorgan substrate flux in the pig
JP3429327B2 (ja) 癌用アミノ酸輸液剤
JPH02121928A (ja) Ｌ−チロシンのジペプチドを含有する栄養輸液組成物
Freund et al. The effect of different intravenous nutritional regimens on renal function during acute renal failure in the rat
Sax Clinical and Metabolic Efficacy of Glutamine‐Supplemented Parenteral Nutrition After Bone Marrow Transplantation. A Randomized, Double‐Blind, Controlled Study TR ZIEGLER, LS YOUNG, K. BENFELL, ET AL Annals of Internal Medicine 116: 821–828, 1992

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 19900421

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

XX Miscellaneous (additional remarks)

Free format text: VERFAHREN ABGESCHLOSSEN INFOLGE VERBINDUNG MIT 88850373.7/0318446 (EUROPAEISCHE ANMELDENUMMER/VEROEFFENTLICHUNGSNUMMER) VOM 25.03.91.